Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Reducing the impact of asthma treatment on climate change

In April 2019, the National Institute for Health and Care Excellence (NICE) published a patient decision aid for inhaler choice in asthma treatment, including comparisons of the devices’ environmental impact as well as usual clinical considerations[1]. The aid suggests taking inhalers’ carbon footprint into account when choosing a device if this is a clinical option for the patient.

The patient decision aid comes as a reaction to the ‘NHS Long Term Plan’, which was published in January 2019 and recommended a greater emphasis on environmentally friendly approaches in the health service.

Metered dose inhalers (MDIs) use hydrofluorocarbons (HFCs) — potent greenhouse gases — as propellants (in which the active ingredient is suspended). Hydrofluorocarbon (HFC)-134a (or 1,1,1,2-tetrafluoroethane), the most commonly used HFC, has a global warming potential of 3,710 over 20 years, meaning that HFC 134a is 3,710 times more potent than carbon dioxide in this regard[2].

Just five doses from an MDI have a global warming potential equivalent to a nine-mile trip in a typical car, with each dose having an estimated carbon footprint of the equivalent of 500g of carbon dioxide[2]. By comparison, dry powder inhalers (DPIs) have a carbon footprint of 20g of carbon dioxide equivalent per dose.

Around 70% of inhalers used in the UK are MDIs, compared with around 10% in Sweden, suggesting that there is considerable scope to increase the use of DPIs in the UK[3].

Pharmacists could play their part in integrating this guidance into primary care by helping patients understand the environmental impact of their MDIs, so that they can have an informed discussion with their clinician at their next asthma review. This could take place during medicines use reviews or as opportunities arise.

Any reduction in carbon emissions as a result of professional interactions between pharmacists and patients is good news while we collectively work to tackle climate change, and its impacts (including impacts on health). In 2018, a World Health Organization assessment concluded that climate change is expected to cause approximately 250,000 additional deaths per year between 2030 and 2050; 38,000 resulting from heat exposure in older people, 48,000 resulting from diarrhoea, 60,000 resulting from malaria, and 95,000 resulting from childhood undernutrition[4].

The UK, which will be relatively sheltered from these effects, should surely do what we can to minimise them.

The patient decision aid can be found at: www.nice.org.uk/guidance/ng80/resources/inhalers-for-asthma-patient-decision-aid-pdf-6727144573.

 

Andrew Baker, practice pharmacist, Ebbw Vale

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206606

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.